
Title of technology: **STD052/07- Fractionated herbal extract demonstrating cholesterol/triglyceride lowering, and a single active compound as potential drug candidate for the treatment of GI disorders**

Date posted: 20 March, 2006

Last updated: 14 November, 2007

Category: Drug discovery

Application: A fractionated herbal extract (STD052) demonstrating cholesterol/triglyceride lowering properties, purified down to a single active compound (STD07), a potential drug candidate for the treatment of GI disorders.

Abstract: STD052 is a fractionated herbal extract from a plant which is broadly used in traditional herbal medicine in China and European countries. However, in large dosages this plant often causes severe side effects such as diarrhea and abdominal cramp. A sophisticated purification process was applied to separate the active ingredients from the herbal extract to minimize its inherent severe side effects. STD052, with a good safety profile, has demonstrated its efficacy in cholesterol/triglyceride lowering, as well as maintaining normal GI function in animal studies.

A single active compound (STD07) was further purified from the herbal extract. In-vitro genetic and animal toxicology studies demonstrated STD07 to be a safe product for further clinical development. STD07 was evaluated for its effectiveness on the DNBS-induced distal colitis, a disease model of IBD in rats. The result showed that STD07 significantly reduced DNBS-induced colon inflammation and decreased adhesion to tissues and colonic ulceration. Thus, STD07 is a potential therapeutic drug candidate for the treatment of GI disorders such as IBD and IBD related pain.

Patent information: US patent filed in 2007

Development status: Preclinical

Type of business relationship sought: Available for out-licensing

Contact: Dr. Yi-wen Chu, Ph.D., head of business development department

Email: yiwen@stpt.com.tw

Company or institute: [SunTen Phytotech Co., Ltd.](#)

